A clinical trial that could significantly improve quality of life for women with moderate arm lymphoedema is underway in Hamilton.
For patients with low-risk early breast cancer, research presented at the San Antonio Breast Cancer Symposium in December 2019 showed that treating only part of the affected breast with accelerated irradiation compares favourably with whole breast irradiation after breast conservation surgery (lumpectomy).
“That was one of my best birthdays ever,” Libby says after her friends, family and supporters gifted more than $2400 to BCAC in honour of her birthday.
BCAC’s Chair Libby Burgess is celebrating her birthday in her ‘lockdown bubble’ on 6 April. By teaming up with The Good Registry, she has turned this event into a fundraiser for BCAC. Libby has asked all her friends and supporters to give to BCAC through her gift registry instead of buying her presents.
We have received excellent information about COVID-19 for women with breast cancer from the Māori Cancer Leadership Group and the Cancer Control Agency, that you will find attached.
BCAC is thrilled that Aotearoa New Zealand has acted so decisively and early in a bid to contain and control COVID-19 (coronavirus). There are sensible rules in place which give our country an opportunity to lead the world in effective management of this deadly virus.
As New Zealand moves to halt the spread of the new flu-like virus COVID-19 (Coronavirus), we have pulled together this information for New Zealanders with breast cancer and their families and whānau. This virus can affect lungs and airways, and has been declared a pandemic by the World Health Organisation.
BCAC media release - 5 March 2020
It is fantastic news that funding for a vital drug for women with advanced breast cancer, palbociclib (Ibrance), will cover the costs for all those who need it , Libby Burgess, Chair of the Breast Cancer Aotearoa Coalition (BCAC) says.
A clinical trial shows that tucatinib, an investigative therapy used in combination with trastuzumab and capecitabine, reduces risk of death at two years by one-third in women with HER2-positive metastatic breast cancer (HER2+ MBC).
BCAC media release, 15 January 2020: Breast Cancer Aotearoa Coalition (BCAC) is delighted to hear that Ibrance (palbociclib) will be funded by PHARMAC from 1 April 2020.